DE602005017475D1 - Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie - Google Patents

Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie

Info

Publication number
DE602005017475D1
DE602005017475D1 DE602005017475T DE602005017475T DE602005017475D1 DE 602005017475 D1 DE602005017475 D1 DE 602005017475D1 DE 602005017475 T DE602005017475 T DE 602005017475T DE 602005017475 T DE602005017475 T DE 602005017475T DE 602005017475 D1 DE602005017475 D1 DE 602005017475D1
Authority
DE
Germany
Prior art keywords
denotes
arg
chelates
conjugates
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005017475T
Other languages
English (en)
Inventor
Dagfinn Lovhaug
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
GE Healthcare AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare AS filed Critical GE Healthcare AS
Publication of DE602005017475D1 publication Critical patent/DE602005017475D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602005017475T 2004-03-04 2005-03-03 Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie Active DE602005017475D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20040953 2004-03-04
PCT/NO2005/000078 WO2005084715A2 (en) 2004-03-04 2005-03-03 Conjugates of angiotensin peptidic analogues and chelating agents for diagnosis and therapy

Publications (1)

Publication Number Publication Date
DE602005017475D1 true DE602005017475D1 (de) 2009-12-17

Family

ID=34918859

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005017475T Active DE602005017475D1 (de) 2004-03-04 2005-03-03 Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie

Country Status (7)

Country Link
US (1) US7763234B2 (de)
EP (1) EP1729823B1 (de)
JP (1) JP2007526300A (de)
CN (1) CN1925876A (de)
AT (1) ATE447417T1 (de)
DE (1) DE602005017475D1 (de)
WO (1) WO2005084715A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0416062D0 (en) * 2004-07-19 2004-08-18 Amersham Plc Improved N4 chelator conjugates
US8568689B1 (en) 2004-09-29 2013-10-29 Ge Healthcare As uPAR-targeting contrast agents
DE602005025911D1 (de) * 2004-11-22 2011-02-24 Ge Healthcare As Kontrastmittel für eine extrazelluläre matrix
WO2010089757A2 (en) * 2008-11-07 2010-08-12 Usv Limited An improved process for synthesis of cyclic octapeptide
US9730916B2 (en) * 2014-02-27 2017-08-15 Chang Gung Memorial Hospital, Keelung Nutritional composition and method for improving heart failure
WO2019169342A1 (en) 2018-03-01 2019-09-06 Trigemina, Inc. Labeled oxytocin and method of manufacture and use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966896A (en) * 1974-09-06 1976-06-29 Mallinckrodt, Inc. Radioimmunoassay for plasma renin activity
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4687659A (en) 1984-11-13 1987-08-18 Salutar, Inc. Diamide-DTPA-paramagnetic contrast agents for MR imaging
ATE197767T1 (de) 1992-01-03 2000-12-15 Rhomed Inc Pharmazeutische anwendungen auf der basis von peptid-metall-ionen
EP0971747B1 (de) * 1996-10-28 2005-12-28 Amersham Health AS Kontrastmittel
DE69735901T2 (de) 1996-10-28 2007-05-10 Ge Healthcare As Verbesseringen an oder in verbindung mit diagnostischen/therapeutischen mitteln
US6230777B1 (en) 1999-02-04 2001-05-15 Midmac Systems, Inc. Filter forming and joining apparatus
NZ521735A (en) 2000-04-12 2004-12-24 Amersham Health As Peptide-based compounds, their use as targeting vectors that bind to receptors associated with antiogenesis such as integrin receptors
AU2001288847A1 (en) 2000-09-07 2002-03-22 Biosyntema Inc. Conformationally constrained labeled peptides for imaging and therapy
KR100932827B1 (ko) 2001-07-10 2009-12-21 지이 헬스케어 에이에스 펩티드계 화합물
GB0116815D0 (en) * 2001-07-10 2001-08-29 Nycomed Amersham Plc Improved chelator conjugates
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
NO20030115D0 (no) 2003-01-09 2003-01-09 Amersham Health As Kontrastmiddel
WO2005044313A2 (en) 2003-11-06 2005-05-19 Amersham Health As Conjugates of angiotensin ii and an imaging moiety

Also Published As

Publication number Publication date
CN1925876A (zh) 2007-03-07
WO2005084715A2 (en) 2005-09-15
WO2005084715A3 (en) 2006-06-15
EP1729823A2 (de) 2006-12-13
JP2007526300A (ja) 2007-09-13
US20070297979A1 (en) 2007-12-27
EP1729823B1 (de) 2009-11-04
US7763234B2 (en) 2010-07-27
ATE447417T1 (de) 2009-11-15

Similar Documents

Publication Publication Date Title
DE602005017475D1 (de) Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie
US11083710B2 (en) PSMA binding ligand-linker conjugates and methods for using
MX348859B (es) Agentes de contraste para formacion de imagenes por perfusion miocardial.
DE69922261D1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
SG152254A1 (en) Contrast agents for myocardial perfusion imaging
HK1107003A1 (en) Mr imaging method for the discrimination between healthy and tumour tissue
ATE439868T1 (de) Targetingmittel für molekulare bilderzeugung
DE60315296D1 (de) Zell-selektives Abgabe System
MA28153A1 (fr) Acides nucléiques se liant spécifiquement à la ghréline biologiquement active
SI1105409T1 (sl) Zascita endogenih peptidov pred peptidazno ucinkovitostjo s konjugacijo na krvne komponente
DE60217090D1 (de) Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
MA29409B1 (fr) Anticorps diriges contre le peptide amyloïde -beta, et methodes pour leurs utilisations
GB0326546D0 (en) Inhibitor imaging agents
WO2009117041A3 (en) Use of pyrene to carry peptides across the blood brain barrier
MXPA04006517A (es) Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
ATE415412T1 (de) Peptide, die atherosklerotische schädigungen binden
NO20025064L (no) RGO koblet til peptider
MA27772A1 (fr) Preparation pharmaceutique orale destinee aux antagonistes de la pompe a protons
ATE466595T1 (de) Verbindungen und methoden für das downregulating der effekte von tgf-beta
ATE435657T1 (de) Therapeutische zubereitung von hochreinem fviia und verfahren zu dessen gewinnung
EP2340845A3 (de) Wiederholungssequenzen des Ca125-Gens und ihre Verwendung bei diagnostischen und therapeutischen Eingriffen
WO2002100885A3 (en) A penta- or tetrapeptide binding to somatostatin receptors and the use of the same
ATE425770T1 (de) Kontrastmittel
ATE289612T1 (de) Diagnostische verwendungen von gegen acetylcholinesterase oder deren c-terminale peptide gerichteten antikörpern
WO2005044313A3 (en) Conjugates of angiotensin ii and an imaging moiety

Legal Events

Date Code Title Description
8364 No opposition during term of opposition